Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Chronic Obstructive Pulmonary Disease | Treatment Algorithms: Claims Data Analysis | US | 2023
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have been gaining traction in the chronic obstructive pulmonary disease (COPD) therapy…
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Migraine (US)
Questions answered What patient shares do key acute therapies and brands garner by line of therapy in newly diagnosed migraine patients? What are the quarterly trends in prescribing of acute…
Bispecific Therapies – Special Topics – Special Topics: Bispecific Therapies (G7 and China)
Bispecific therapies represent a class of drug with two binding sites directed at two different antigens or epitopes. This dual action makes bispecific therapies a promising approach to improve…
Acute Myeloid Leukemia – Unmet Need – Unmet Need – First-Line Intensive-Induction-Eligible Acute Myeloid Leukemia (US/EU)
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, originating from mutant myeloid precursor cells. Presently, the AML drug market is dominated by chemotherapy backbones, but…
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Nonalcoholic Steatohepatitis (US/EU)
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…
